TCG Crossover Management LLC bought a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,801,763 shares of the company's stock, valued at approximately $44,856,000. Upstream Bio makes up approximately 4.4% of TCG Crossover Management LLC's portfolio, making the stock its 7th largest position. TCG Crossover Management LLC owned 5.23% of Upstream Bio at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of UPB. US Bancorp DE bought a new position in Upstream Bio during the fourth quarter valued at $27,000. Legal & General Group Plc bought a new position in shares of Upstream Bio in the 4th quarter valued at about $28,000. Summit Investment Advisors Inc. bought a new position in shares of Upstream Bio in the 4th quarter valued at about $30,000. Tower Research Capital LLC TRC bought a new stake in Upstream Bio during the fourth quarter worth approximately $47,000. Finally, Corebridge Financial Inc. bought a new stake in Upstream Bio during the fourth quarter worth approximately $142,000.
Upstream Bio Price Performance
Shares of NASDAQ:UPB traded down $0.36 during trading on Friday, hitting $8.64. The company had a trading volume of 484,378 shares, compared to its average volume of 324,226. The company has a fifty day simple moving average of $7.96 and a two-hundred day simple moving average of $14.07. Upstream Bio, Inc. has a one year low of $5.14 and a one year high of $29.46.
Upstream Bio Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Read More
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
